Earlier this year, when the administration proposed deep cuts to the National Institutes of Health, lawmakers from both parties swiftly and rightly pushed back. Slashing medical research funding, they recognized, would jeopardize the discovery of breakthrough treatments that patients desperately need.

The NIH plays a crucial role in supporting basic biomedical research. In 2024, it awarded $37 billion in grants to scientists nationwide. Lawmakers understood that undermining this investment in the name of budget savings could ultimately slow progress against the most pressing diseases.

That’s why it’s baffling that many of the same lawmakers who voted to protect NIH funding are now cheering President Trump’s plan to impose “most favored nation” price controls on drugs, a policy that could

See Full Page